Sirolimus in solid organ transplantation: current therapies and new frontiers

Area of Science:

• Immunopharmacology
• Cell Biology

Background:

• Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor.
• SRL inhibits cell cycle progression, providing immunosuppressive effects.
• Combined SRL-cyclosporine therapy shows promise for immunosuppression.

Purpose of the Study:

• To evaluate the safety and efficacy of Sirolimus (SRL) in various therapeutic contexts.
• To explore the potential of SRL as an antiatherogenic and antineoplastic agent.
• To investigate the long-term safety of SRL with low-dose calcineurin inhibitors and its role as a corticosteroid-sparing agent.

Main Methods:

• Pharmacodynamic analysis of SRL in combination therapies.
• Assessment of SRL's side effect profile, including nephrotoxicity, hyperlipidemia, and myelosuppression.
• Evaluation of SRL's antiatherogenic and antineoplastic properties.

Main Results:

• SRL is relatively non-nephrotoxic as monotherapy but enhances calcineurin inhibitor toxicity.
• Common side effects include hyperlipidemia and myelosuppression; less common effects include impaired wound healing, proteinuria, edema, and pneumonitis.
• SRL demonstrates potential antiatherogenic and antineoplastic effects.

Conclusions:

• SRL has a complex safety profile, particularly when combined with calcineurin inhibitors.
• Further studies are required to establish long-term safety with reduced calcineurin inhibitor doses.
• The efficacy of SRL as a corticosteroid-sparing agent needs validation through controlled trials.